Manufacturer of Controlled Substances Registration: Research Triangle Institute, 3988-3989 [2015-01301]
Download as PDF
<![CDATA[
3988
Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices
DEPARTMENT OF JUSTICE
ingredients (APIs) for sale to its
customers.
Drug Enforcement Administration
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Boehringer
Ingelheim Chemical, Inc.
ACTION:
Controlled
Substance
[FR Doc. 2015–01289 Filed 1–23–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Notice of registration.
Boehringer Ingelheim
Chemical, Inc. applied to be registered
as a manufacturer of certain basic
classes of controlled substances. The
DEA grants Boehringer Ingelheim
Chemical, Inc. registration as a
manufacturer of the controlled
substances.
Drug Enforcement Administration
By notice
dated May 28, 2014, and published in
the Federal Register on June 4, 2014, 79
FR 32321, Boehringer Ingelheim
Chemical, Inc., 2820 N. Normandy
Drive, Petersburg, Virginia 23805–9372,
applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted to this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Boehringer Ingelheim Chemical, Inc. to
manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances:
SUMMARY:
SUMMARY:
SUPPLEMENTARY INFORMATION:
emcdonald on DSK67QTVN1PROD with NOTICES
Controlled substance
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals. In
reference to methadone intermediate
(9254) the company plans to produce
methadone HCL active pharmaceutical
VerDate Sep<11>2014
18:48 Jan 23, 2015
Jkt 235001
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: S & B
Pharma, Inc.
ACTION:
S & B Pharma, Inc. applied to
be registered as a manufacturer of
certain basic classes of controlled
substances. The DEA grants S & B
Pharma, Inc. registration as a
manufacturer of those controlled
substances.
SUPPLEMENTARY INFORMATION: By notice
dated July 1, 2014, and published in the
Federal Register on July 8, 2014, 79 FR
38564, S & B Pharma, Inc., DBA Norac
Pharma, 405 South Motor Avenue,
Azusa, California 91702–3232 applied
to be registered as a manufacturer of
certain basic classes of controlled
substances. No comments or objections
were submitted to this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of S &
B Pharma, Inc. to manufacture the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Methamphetamine (1105) ............
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for use in product development and for
commercial sales to its customers.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01287 Filed 1–23–15; 8:45 am]
BILLING CODE P
Notice of registration.
Controlled
Substance
Pentobarbital (2270) .....................
Nabilone (7379) ............................
4-Anilino-N-phenethyl-4-piperidine
(ANPP) (8333).
Tapentadol (9780) ........................
Fentanyl (9801) ............................
Schedule
I
I
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Research
Triangle Institute
ACTION:
Notice of registration.
Research Triangle Institute
applied to be registered as a
manufacturer of certain basic classes of
controlled substances. The DEA grants
Research Triangle Institute registration
as a manufacturer of those controlled
substances.
SUPPLEMENTARY INFORMATION: By notice
dated July 2, 2014, and published in the
Federal Register on July 14, 2014, 79 FR
40781, Research Triangle Institute,
Kenneth S. Rehder, Ph.D., Hermann
Building East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, applied to be registered
as a manufacturer of certain basic
classes of controlled substances. No
comments or objections were submitted
to this notice.
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823(a) and
determined that the registration of
Research Triangle Institute to
manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
SUMMARY:
E:\FR\FM\26JAN1.SGM
26JAN1
Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:
Controlled
substance
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:
Controlled substance
I
I
II
Schedule
[Docket No. DEA–392]
Codeine-N-oxide (9053) ...............
I=≥01≥≤Dihydromorphine (9145) ..
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
Manufacturer of Controlled
Substances Registration: Noramco,
Inc.
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
The company will manufacture
marihuana and cocaine derivatives for
use by their customers in analytical kits,
reagents, and reference standards as
directed by the National Institute on
Drug Abuse.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01301 Filed 1–23–15; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
ACTION:
Notice of registration.
Noramco, Inc. applied to be
registered as a manufacturer of certain
basic classes of controlled substances.
The DEA grants Noramco, Inc.
registration as a manufacturer of those
controlled substances.
SUPPLEMENTARY INFORMATION:
By notice dated January 14, 2014, and
published in the Federal Register on
January 22, 2014, 79 FR 3627, Noramco,
Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted to this notice.
The Drug Enforcement Administration
(DEA) has considered the factors in 21
U.S.C. 823(a) and determined that the
registration of Noramco, Inc. to
manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:48 Jan 23, 2015
Jkt 235001
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01303 Filed 1–23–15; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (NIJ) Docket No. 1680]
Offender Tracking Systems Market
Survey
AGENCY:
National Institute of Justice,
DOJ.
Notice of Request for
Information.
ACTION:
The National Institute of
Justice (NIJ) is soliciting information in
relation to the upcoming National
Criminal Justice Research, Test, and
Evaluation Center (NIJ RT&E Center)
‘‘Market Survey of Location-based
Offender Tracking Technologies.’’ This
market survey will be published by NIJ
to assist prospective agencies in their
assessment of relevant information on
commercially available offender
tracking systems (OTS) marketed for use
by the criminal justice community, prior
to making purchasing decisions. The NIJ
SUMMARY:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
3989
RT&E Center invites comments with
regard to the market survey, including
which categories of information are
appropriate for comparison. Vendors of
such technology are also invited to
provide promotional material (e.g., slick
sheet) and images of the technology
(e.g., a print-quality photograph).
DATES: Responses to this request will be
accepted through 11:59 p.m. Eastern
Time on February 25, 2015.
ADDRESSES: Responses to this request
may be submitted electronically in the
body of or as an attachment to an email
sent to administrator@nijrtecenter.org
with the recommended subject line
‘‘OTS Federal Register Response’’.
Questions and responses may also be
sent by mail (please allow additional
time for processing) to the address:
National Criminal Justice Research, Test
and Evaluation Center, ATTN: OTS
Federal Register Response, Johns
Hopkins University Applied Physics
Laboratory, 11100 Johns Hopkins Road,
Mail Stop 17N444, Laurel, MD 20723–
6099.
FOR FURTHER INFORMATION CONTACT: For
more information on this request for
information contact Steven Taylor (NIJ
RT&E Center) at (443) 778–9348 or
administrator@nijrtecenter.org. For
more information on the NIJ RT&E
Center, visit https://nij.gov/funding/
awards/Pages/awarddetail.aspx?award=2013-MU-CX-K111
and view the description or contact Jack
Harne, by telephone at 202–616–2911 or
by email at Jack.Harne@usdoj.gov.
Please note that these are not toll-free
telephone numbers.
SUPPLEMENTARY INFORMATION:
Information Sought: The NIJ RT&E
Center seeks input to its upcoming
‘‘Market Survey of Location-based
Offender Tracking Technologies.’’ This
technology, consisting of hardware and
software component, is designed to
determine and report at programmed
intervals the geographic location at a
particular time of an individual who is
subject to criminal justice system
supervision. Whether an agency faces a
mandate to track domestic violence or
sex offenders, has a need to more
closely monitor higher risk offenders, or
is looking for confinement alternatives
for low-risk offenders, this technology
can often be a practical tool for
supervising and managing select
individuals.
This market survey will be published
by NIJ to assist prospective agencies in
their assessment of relevant information
on commercially available OTS
marketed for use by the criminal justice
community, prior to making purchasing
decisions. Vendors who respond to this
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 80, Number 16 (Monday, January 26, 2015)]
[Notices]
[Pages 3988-3989]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01301]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Research
Triangle Institute
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Research Triangle Institute applied to be registered as a
manufacturer of certain basic classes of controlled substances. The DEA
grants Research Triangle Institute registration as a manufacturer of
those controlled substances.
SUPPLEMENTARY INFORMATION: By notice dated July 2, 2014, and published
in the Federal Register on July 14, 2014, 79 FR 40781, Research
Triangle Institute, Kenneth S. Rehder, Ph.D., Hermann Building East
Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina
27709, applied to be registered as a manufacturer of certain basic
classes of controlled substances. No comments or objections were
submitted to this notice.
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823(a) and determined that the registration of
Research Triangle Institute to manufacture the basic classes of
controlled substances is consistent with the public interest and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The DEA investigated the company's
maintenance of effective controls against diversion by inspecting and
testing the company's physical security systems, verifying the
company's compliance with state and local laws, and reviewing the
company's background and history.
[[Page 3989]]
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Cocaine (9041)............................. II
------------------------------------------------------------------------
The company will manufacture marihuana and cocaine derivatives for
use by their customers in analytical kits, reagents, and reference
standards as directed by the National Institute on Drug Abuse.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01301 Filed 1-23-15; 8:45 am]
BILLING CODE P
